Psoriasis Clinical Trials 2024: FDA Approvals, Medication, Therapies, Treatment Market, MOA, ROA and Companies Involved by DelveInsight | Johnson and Johnson, Janssen Biotech, Leo Pharma, Merck, Novartis, Pfizer, AbbVie, Amgen, AstraZeneca, Biogen, etc

(Albany, United States) As per DelveInsight's assessment, globally, Psoriasis pipeline constitutes 80+ key companies continuously working towards developing 80+ Psoriasis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Psoriasis Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Psoriasis Market.

The Psoriasis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Request for Sample Report @ https://www.delveinsight.com/sample-request/psoriasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key takeaways from the Psoriasis Pipeline Report:
• Psoriasis Companies across the globe are diligently working toward developing novel Psoriasis treatment therapies with a considerable amount of success over the years.
• Psoriasis companies working in the treatment market are Fresh Tracks Therapeutics, Inmagene, SFA Therapeutics, Palobiofarma, Sun Pharmaceutical Industries Limited, Biohaven Pharmaceuticals, Inc., Dr. Reddy's, MetrioPharm, Celltrion, Amgen, Can-Fite Biopharma, and others, are developing therapies for the Psoriasis treatment
• Emerging Psoriasis therapies in the different phases of clinical trials are- FRTX-03, IMG-008, SFA 002, PBF-1650, SCD-044, Rimegepant, PPC-06, MP1032, CT-P43, ABP 654, Piclidenoson, and others are expected to have a significant impact on the Psoriasis market in the coming years.
• In May 2024, InnoCare Pharma has completed enrollment of participants in the Phase II clinical trial of ICP-488, intended for patients with moderate to severe plaque psoriasis. This milestone represents a key advancement in the drug's development as a tyrosine kinase 2 (TYK2) JH2 allosteric inhibitor. The trial, which is randomized, multi-center, double-blind, and placebo-controlled, aims to evaluate the safety, effectiveness, pharmacokinetics (PK), and pharmacodynamics (PD) of ICP-488 specifically in Chinese adult patients.
• In February 2024, Johnson & Johnson announced today that the Phase 2b FRONTIER 1 trial results for JNJ-2113 have been published in the New England Journal of Medicine (NEJM). JNJ-2113 is an investigational oral peptide inhibitor designed to selectively block the IL-23 receptor, marking a significant advancement in targeted therapy. IL-23 is crucial in activating pathogenic T-cells involved in moderate-to-severe plaque psoriasis (PsO), as well as other IL-23-mediated inflammatory conditions in dermatology and gastroenterology. The FRONTIER 1 trial successfully met its primary and all secondary efficacy endpoints in assessing JNJ-2113's effectiveness in adults with moderate-to-severe plaque PsO.
• In April 2023, Can-Fite BioPharma revealed that it has obtained a favorable viewpoint from the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA) concerning the proposal for a registration strategy for a critical Phase III clinical trial intended for treating moderate to severe psoriasis. The agency has approved the pivotal Phase III investigation along with affirming the safety of the 3 mg twice-daily dosage of Piclidenoson.

Psoriasis Overview
Psoriasis is a chronic autoimmune condition that causes the rapid buildup of skin cells. This buildup leads to scaling on the skin's surface. Inflammation and redness around the scales are also quite common. Psoriasis typically involves patches of abnormal skin that are red, itchy, and scaly. These patches may vary in severity from small, localized areas to complete body coverage.

Get a Free Sample PDF Report to know more about Psoriasis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/psoriasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Emerging Psoriasis Drugs Under Different Phases of Clinical Development Include:
• FRTX-03: Fresh Tracks Therapeutics
• IMG-008: Inmagene
• SFA 002: SFA Therapeutics
• PBF-1650: Palobiofarma
• SCD-044: Sun Pharmaceutical Industries Limited
• Rimegepant: Biohaven Pharmaceuticals, Inc.
• PPC-06: Dr. Reddy's
• MP1032: MetrioPharm
• CT-P43: Celltrion
• ABP 654: Amgen
• Piclidenoson: Can-Fite Biopharma

Psoriasis Route of Administration
Psoriasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Psoriasis Molecule Type
Psoriasis Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Psoriasis Pipeline Therapeutics Assessment
• Psoriasis Assessment by Product Type
• Psoriasis By Stage and Product Type
• Psoriasis Assessment by Route of Administration
• Psoriasis By Stage and Route of Administration
• Psoriasis Assessment by Molecule Type
• Psoriasis by Stage and Molecule Type

DelveInsight's Psoriasis Report covers around 80+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Psoriasis product details are provided in the report. Download the Psoriasis pipeline report to learn more about the emerging Psoriasis therapies at:
https://www.delveinsight.com/sample-request/psoriasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key companies in the Psoriasis Therapeutics Market include:
Key companies developing therapies for Psoriasis are - AbbVie Inc., Amgen Inc., AstraZenca, Biogen Idec, Boehringer Ingelheim, Celgene Corporation, Dr.Reddy`s Laboratories, Eli Lilly and Company, Forward Pharma, Johnson and Johnson (Janssen Biotech Inc.), Leo Pharma AS, Merck and Co. Inc., Novartis AG, Pfizer Inc., Stiefel Laboratories Inc., Sun pharmaceutical Industries Limited, Takeda Pharmaceutical Company Limited, UCB SA, Valeant Pharmaceuticals, and others.

Psoriasis Pipeline Analysis:
The Psoriasis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Psoriasis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Psoriasis Treatment.
• Psoriasis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Psoriasis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Psoriasis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Psoriasis drugs and therapies-
https://www.delveinsight.com/sample-request/psoriasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Psoriasis Pipeline Market Drivers
• Increasing prevalence of Psoriasis across the globe, increasing combinational therapies, an increase witnessed in Biological therapy approvals for Psoriasis are some of the important factors that are fueling the Psoriasis Market.

Psoriasis Pipeline Market Barriers
• However, side effects associated with the treatment, high-cost treatment and Unfavourable Reimbursement policies and other factors are creating obstacles in the Psoriasis Market growth.

Scope of Psoriasis Pipeline Drug Insight
• Coverage: Global
• Key Psoriasis Companies: Fresh Tracks Therapeutics, Inmagene, SFA Therapeutics, Palobiofarma, Sun Pharmaceutical Industries Limited, Biohaven Pharmaceuticals, Inc., Dr. Reddy's, MetrioPharm, Celltrion, Amgen, Can-Fite Biopharma, and others
• Key Psoriasis Therapies: FRTX-03, IMG-008, SFA 002, PBF-1650, SCD-044, Rimegepant, PPC-06, MP1032, CT-P43, ABP 654, Piclidenoson, and others
• Psoriasis Therapeutic Assessment: Psoriasis current marketed and Psoriasis emerging therapies
• Psoriasis Market Dynamics: Psoriasis market drivers and Psoriasis market barriers

Request for Sample PDF Report for Psoriasis Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/psoriasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Psoriasis Report Introduction
2. Psoriasis Executive Summary
3. Psoriasis Overview
4. Psoriasis- Analytical Perspective In-depth Commercial Assessment
5. Psoriasis Pipeline Therapeutics
6. Psoriasis Late Stage Products (Phase II/III)
7. Psoriasis Mid Stage Products (Phase II)
8. Psoriasis Early Stage Products (Phase I)
9. Psoriasis Preclinical Stage Products
10. Psoriasis Therapeutics Assessment
11. Psoriasis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Psoriasis Key Companies
14. Psoriasis Key Products
15. Psoriasis Unmet Needs
16 . Psoriasis Market Drivers and Barriers
17. Psoriasis Future Perspectives and Conclusion
18. Psoriasis Analyst Views
19. Appendix
20. About DelveInsight

Trending Reports:
• Bladder Cancer Market: https://www.delveinsight.com/report-store/bladder-cancer-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Cardiac Biomarkers Testing Devices Market: https://www.delveinsight.com/report-store/cardiac-biomarkers-testing-devices-market
• Central Venous Catheters Market: https://www.delveinsight.com/report-store/central-venous-catheters-market
• Epilepsy Market: https://www.delveinsight.com/report-store/epilepsy-market
• Gaucher Disease Market: https://www.delveinsight.com/report-store/gauchers-disease-market
• Generalized Pustular Psoriasis Market: https://www.delveinsight.com/report-store/generalized-pustular-psoriasis-market
• Healthcare Due Diligence Services: https://www.delveinsight.com/consulting/due-diligence-services
• Hemodynamic Monitoring Systems Market: https://www.delveinsight.com/report-store/hemodynamic-monitoring-system-market
• Implantable Infusion Pumps Market: https://www.delveinsight.com/report-store/implantable-infusion-pumps-market
• Neuromodulation Devices Market: https://www.delveinsight.com/report-store/neuromodulation-devices-market
• Neurostimulation Devices Market: https://www.delveinsight.com/report-store/neurostimulation-devices-market
• Neurotrophic Keratitis Market: https://www.delveinsight.com/report-store/neurotrophic-keratitis-market
• Post Traumatic Stress Disorder Market: https://www.delveinsight.com/report-store/post-traumatic-stress-disorder-ptsd-market
• Post-bariatric Hypoglycemia Market: https://www.delveinsight.com/report-store/post-bariatric-hypoglycemia-market
• Absssi Market: https://www.delveinsight.com/report-store/acute-bacterial-skin-and-skin-structure-infections-market
• Acute Gout Flare Market: https://www.delveinsight.com/report-store/acute-gout-flare-market
• Adrenoleukodystrophy Market: https://www.delveinsight.com/report-store/adrenoleukodystrophy-market
• Adult Myopia Market: https://www.delveinsight.com/infographics/adult-myopia-market
• Alopecia Areata Market: https://www.delveinsight.com/report-store/alopecia-areata-market
• Alpha-mannosidosis Market: https://www.delveinsight.com/report-store/alpha-mannosidosis-market
• Androgenetic Alopecia Market: https://www.delveinsight.com/report-store/androgenetic-alopecia-market
• Anemia In Ckd Market: https://www.delveinsight.com/report-store/anemia-in-chronic-kidney-disease-market
• Anterior Cruciate Ligament Injuries Market: https://www.delveinsight.com/report-store/anterior-cruciate-ligament-injuries-market
• Artificial Lung Devices Market: https://www.delveinsight.com/report-store/artificial-lung-devices-pipeline-insight-and-competitive-landscape
• Automated External Defibrillators Market: https://www.delveinsight.com/report-store/automated-external-defibrillator-aed-market
• Biochips Market: https://www.delveinsight.com/blog/biochips-market-landscape
• Cardiac Amyloidosis Market: https://www.delveinsight.com/report-store/cardiac-amyloidosis-market
• Carpal Tunnel Syndrome Market: https://www.delveinsight.com/report-store/carpal-tunnel-release-system-market
• Centronuclear Myopathy Market: https://www.delveinsight.com/report-store/centronuclear-myopathy-cnm-pipeline-insight
• Chronic Rhinosinustis Market: https://www.delveinsight.com/report-store/chronic-rhinosinusitis-with-nasal-polyps-market
• Competitive Intelligence Pharma: https://www.delveinsight.com/blog/competitive-intelligence-in-healthcare-sector
• Concussions Market Size: https://www.delveinsight.com/report-store/concussions-market
• Cutaneous T Cell Lymphoma Market: https://www.delveinsight.com/infographics/cutaneous-t-cell-lymphoma-ctcl-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting/conference-coverage-services

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.